Gainers & losers: Amid a mixed trend with the Asian market, the domestic market was under pressure to sell for the third consecutive day. The central bank RBI cut the repo rate after nearly five years but it failed to do good mood in the market. On the day of the last MPC meeting of this financial year 2025, BSE Sensex (BSE SENSEX) is also lost on 197.97 points i.e. 0.25% to 77,860.19 and Nifty 50 (NIFTY 50) also closed 0.18% i.e. 43.40 points. Talking about individual stocks, some stocks had a sharp stir due to their special activity. Details are being given here, including the cause of fluctuations about these shares.
These shares climb up at the speed of rocket
Bharti Airtel. Current price: ₹ 1677.80 (+3.60%)
While profits increased by 5 times in the December quarter, the shares also jumped 5.46% to ₹ 1708.00 in Intra-Day today. In the December quarter, the company’s net profit rose from ₹ 2442 crore to ₹ 14781 crore on an annual basis. During this period, revenue also rose 19% to 45,129 crore. HSBC has advised to buy it at a target price of ₹ 1940. The board of Airtel has also approved the sale of about 12700 telecom towers Indus towers for ₹ 2,174.6 crore but will also have to get regulatory approval.
Tata Steel. Current price: ₹ 138.30 (+4.34%)
JSPL. Current price: ₹ 842.75 (+4.09%)
Metal stocks rose in the hope of increasing demand due to reduction in interest rates. Tata Steel jumped 4.68% in Intra-Day to ₹ 138.75 and JSPL (Jindal Steel & Power) 4.82% jumped to ₹ 848.60. Tata Steel was the top gainer of Sensex today.
Indus Towers. Current price: ₹ 362.80 (+1.92%)
Airtel’s board has approved to sell around 12700 telecom towers to Indus Towers for ₹ 2,174.6 crore. On this, the shares of Indus Towers jumped 3.76% in Intra-Day to ₹ 369.35 today.
Ramco Cements. Current price: ₹ 895.60 (+0.61%)
The shares of Ramco Cements jumped 2.01% to ₹ 908.10 on the December quarter result. In the December quarter, the company’s net profit rose 116% to ₹ 182.38 crore on an annual basis. However, during this time the company’s revenue slipped 6% to ₹ 1,983 crore.
These shares collapsed
NCC. Current price: ₹ 207.50 (-12.63%)
NCC shares included in Rekha Jhunjhunwala’s portfolio fell 14.59% to ₹ 202.85 today in intra-day on the weak result of the December quarter. In the December quarter, the company’s consolidated net profit fell nearly 12.5 per cent to Rs. 193.18 crore on a annual basis. EBITDA also slipped 16.6 per cent to ₹ 420.9 crore during this period and Ebitda margin declined from 9.6% to 7.9%. Rekha Jhunjhunwala’s company has 10.63% shareholding.
Britannia. Current price: ₹ 4868.45 (-1.82%)
Britannia is planning to increase the prices of its products by 4-4.5 per cent by the last of the last of 2025 this financial year. It put pressure on the shares and today in intra-day it fell 2.32% to ₹ 4843.90. The company said that 2 per cent prices were increased in the December quarter and now this quarter may increase by 4-4.5 per cent.
Ola Electric Mobility. Current price: ₹ 70.02 (-2.56%)
Due to the loss of Ola electric mobility and increase in the December quarter, shares also fell 4.88% in INTRAD to ₹ 68.35 today. In the December quarter, the company’s consolidated net loss rose by more than 50% to ₹ 564 crore. During this time, the company’s revenue also fell 19.4% to ₹ 1045 crore. However, it remains the top company in the market with 25.5% market share.
ITC. Current price: ₹ 430.90 (-2.38%)
When ITC announced a deal to buy Prasuma, a frozen, child and ready-to-kuk foods, the market did not like it at the moment and the stocks fell 2.92% in Intra-Day to ₹ 428.50 today. Today it is the top loser on the Sensex. ITC will buy it in three years and will buy 43.8 per cent stake in the first installment and then it will buy the rest of the installments by June 2028. Apart from this, the results of the December quarter also put pressure on the shares. In the December quarter, the company’s net profit rose just 1.02 per cent to ₹ 5,638.3 crore and the revenue rose 8.6 per cent to ₹ 17,052.8 crore.
Akums drugs. Current price: ₹ 560.60 (-2.42%)
On the weak result of the December quarter, Ekams Drugs and Pharma shares fell 3.28% in Intra-Day to ₹ 555.65. In the December quarter, the company’s net profit fell 66% on an annual basis to ₹ 65.18 crore and the revenue slipped 7% to ₹ 1010.4 crore.
(All expressions from BSE)
Disclaimer: Advice or idea experts/brokerage firms on Moneycontrol.com have their own personal views. The website or management is not responsible for this. Moneycontrol advises to users that always seek the advice of certified experts before taking any investment decision.